Company Filing History:
Years Active: 2014-2017
Title: Innovations by Inventor Jakob Eberhard
Introduction
Jakob Eberhard is a notable inventor based in Lund, Sweden. He has made significant contributions to the field of cancer research, particularly in the development of methods for predicting treatment responses in bladder cancer patients. With a total of 2 patents, Eberhard's work is paving the way for advancements in personalized medicine.
Latest Patents
Eberhard's latest patents focus on innovative methods for determining patient prognosis and treatment responses. One of his patents, titled "RBM3 in Bladder Cancer," outlines a method for assessing whether a patient with bladder cancer belongs to a group with a better prognosis. This method involves evaluating the amount of RBM3 in a sample from the patient and comparing it to a reference value. If the sample value is higher, the patient is classified into a group with a more favorable prognosis.
Another significant patent is "Prediction of Response to Platinum-Based Therapy." This invention provides a method for determining whether a cancer patient is likely to respond to platinum-based therapy. Similar to his previous patent, this method evaluates the amount of RBM3 protein or mRNA in a sample and compares it to a reference value to classify the patient accordingly.
Career Highlights
Jakob Eberhard is currently associated with Atlas Antibodies AB, a company known for its focus on antibody-based research and diagnostics. His work at Atlas Antibodies has allowed him to collaborate with other experts in the field, enhancing the impact of his research.
Collaborations
Eberhard has worked alongside notable colleagues, including Karin Jirström, who shares a commitment to advancing cancer research. Their collaborative efforts contribute to the development of innovative solutions in the medical field.
Conclusion
Jakob Eberhard's contributions to cancer research through his patents demonstrate his commitment to improving patient outcomes. His innovative methods for predicting treatment responses are essential advancements in personalized medicine.